UNISOUND AI TECHNOLOGY CO., LTD.
雲知聲智能科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9678)

REVENUE FORECAST FOR THE FIRST HALF OF 2026

This announcement is made by Unisound AI Technology Co., Ltd. (the "**Company**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

I. ESTIMATED REVENUE

The board of directors (the "**Board**") of the Company wishes to inform the shareholders and potential investors of the Company that, based on a preliminary review of the unaudited consolidated management accounts of the Company for the period ended June 30, 2026 (the "**First Half of 2026**") and the information currently available to the Company, for the First Half of 2026, the Company expects to record a total operating revenue of RMB530 million to RMB580 million, representing an increase of **31% to 43%** compared to the same period in 2025. The revenue growth rate may **double** compared to the same period in 2025, demonstrating the Company's strong growth momentum. By business segment, for the First Half of 2026, the intelligent agent business powered by large model capabilities expects to record a revenue of RMB515 million to RMB550 million, representing an increase of **200% to 220%** compared to the same period in 2025. The direct Token invocation business of large model developed newly by the Company this year expects to record a revenue of approximately RMB30 million for the First Half of 2026, with a gross profit margin of not less than **60%**, of which Token invocation revenue in the second quarter of 2026 is approximately RMB25 million, representing a quarter-on-quarter increase of approximately **500%** compared to the first quarter of 2026. The Company's revenue demonstrates strong sustainability. In the First Half of 2026, revenue from repeat purchases is expected to account for over **60%** of total revenue, with repeat purchase revenue growing by **40%** year-on-year, fully demonstrating the high customer stickiness and revenue continuity of its core business.

II. RISK WARNING

As of the date of this announcement, the Company is still in the process of finalizing its results for the First Half of 2026. The information contained in this announcement is based merely on a preliminary assessment by the Company of the information currently available, and is not the final figures. Such information has not been reviewed by the Company's auditors or the Audit Committee of the Board of Directors, and does not represent that the Company will ultimately record a profit or loss for the period ended June 30, 2026.

The estimated revenue contained in this announcement is not intended, and should not be construed, as a profit forecast of the Company's overall results for the First Half of 2026, or a representation, whether express or implied, of the Company's overall profitability for the First Half of 2026. The Company has not yet obtained the final and definitive figures for its overall results for the First Half of 2026. Such overall results may be subject to further adjustments and finalization, and may differ from those disclosed in this announcement. The specific financial data subject to the Company's subsequent announcement of its reviewed interim results for 2026.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company, and read carefully the announcement of the interim results of the Group for the six months ended 30 June 2026, which is expected to be published in August 2026.

By Order of the Board
Unisound AI Technology Co., Ltd.
Dr. Huang Wei
Executive Director and Chief Executive Officer

Beijing, the PRC
July 22, 2026

As at the date of this announcement, the Board of Directors of the Company comprises: (i) Dr. Liang Jia'en, Dr. Huang Wei, Dr. Kang Heng, Dr. Li Xiaohan and Dr. Liu Shengping as executive directors; and (ii) Mr. Hu Jianjun, Dr. Fan Jian, Dr. Jin Huihua and Dr. Zhang Kun as independent non-executive directors.